Your browser doesn't support javascript.
loading
Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial.
John, Thomas; Grohé, Christian; Goldman, Jonathan W; Shepherd, Frances A; de Marinis, Filippo; Kato, Terufumi; Wang, Qun; Su, Wu-Chou; Choi, Jin Hyuk; Sriuranpong, Virote; Melotti, Barbara; Fidler, Mary J; Chen, Jun; Albayaty, Muna; Stachowiak, Marta; Taggart, Sarah; Wu, Yi-Long; Tsuboi, Masahiro; Herbst, Roy S; Majem, Margarita.
Afiliação
  • John T; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia. Electronic address: Tom.John@petermac.org.
  • Grohé C; Klinik für Pneumologie - Evangelische Lungenklinik Berlin Buch, Berlin, Germany.
  • Goldman JW; David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California.
  • Shepherd FA; Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre and the University of Toronto, Toronto, Ontario, Canada.
  • de Marinis F; Thoracic Oncology Division, European Institute of Oncology (IEO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.
  • Kato T; Department of Thoracic Oncology, Kanagawa Cancer Center, Asahi Ward, Yokohama, Japan.
  • Wang Q; Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
  • Su WC; Department of Oncology, National Cheng Kung University, Tainan, Taiwan.
  • Choi JH; Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Republic of Korea.
  • Sriuranpong V; Division of Medical Oncology, Faculty of Medicine, Chulalongkorn University and the King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
  • Melotti B; Division of Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Fidler MJ; Hematology, Oncology and Cell Therapy, Department of Medicine, Rush University Medical Center, Chicago, Illinois.
  • Chen J; Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, People's Republic of China.
  • Albayaty M; Oncology Research & Development, AstraZeneca, Cambridge, United Kingdom.
  • Stachowiak M; Late Oncology Research & Development, AstraZeneca, Warsaw, Poland.
  • Taggart S; Oncology Biometrics, AstraZeneca, Cambridge, United Kingdom.
  • Wu YL; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, People's Republic of China.
  • Tsuboi M; Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Herbst RS; Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, Connecticut.
  • Majem M; Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
J Thorac Oncol ; 18(9): 1209-1221, 2023 09.
Article em En | MEDLINE | ID: mdl-37236398
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Clinical_trials / Guideline / Qualitative_research Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Clinical_trials / Guideline / Qualitative_research Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article